Headlines about Strongbridge Biopharma PLC (NASDAQ:SBBP) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Strongbridge Biopharma PLC earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.3764641864424 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research lowered shares of Strongbridge Biopharma PLC from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Oppenheimer Holdings, Inc. assumed coverage on shares of Strongbridge Biopharma PLC in a report on Thursday, August 10th. They set an “outperform” rating and a $12.00 target price on the stock. ValuEngine raised shares of Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Finally, HC Wainwright reissued a “buy” rating on shares of Strongbridge Biopharma PLC in a report on Wednesday, May 17th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $11.94.
Shares of Strongbridge Biopharma PLC (SBBP) opened at 6.25 on Wednesday. The company’s market capitalization is $220.84 million. Strongbridge Biopharma PLC has a 12-month low of $2.00 and a 12-month high of $8.85. The firm’s 50-day moving average is $6.85 and its 200-day moving average is $5.28.
Strongbridge Biopharma PLC (NASDAQ:SBBP) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.34) EPS for the quarter, meeting analysts’ consensus estimates of ($0.34). The business had revenue of $1.53 million for the quarter, compared to the consensus estimate of $0.84 million. On average, equities analysts predict that Strongbridge Biopharma PLC will post ($2.48) EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Strongbridge Biopharma PLC (SBBP) Earning Somewhat Favorable News Coverage, Report Shows” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://sportsperspectives.com/2017/09/13/strongbridge-biopharma-plc-sbbp-earning-somewhat-favorable-news-coverage-report-shows.html.
About Strongbridge Biopharma PLC
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.
Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.